BCL2 and acute myeloid leukemia: Furthermore, the combination of venetoclax (inhibitor of the anti-apoptopic protein BCL-2) and azacitidine has been shown to target mitochondrial metabolism through inhibition of the glutathionylation of complex II of the electron transport chain (45) and diminishes the uptake of global amino acids in primary patient AML stem cells (46).